Market Report

Global Oncology Liquid Biopsy Manufacturing Market (2018-2023) and Stakeholder Toolkit (Founders/Entrepreneurs, Investors, Regulators and Payers, Biopharma Partners)

Liquid Biopsy Market Size, Growth and Trends (2018-2023)

PURCHASE THE REPOrt

Author: Stephane Budel, Jessica Lee, Mika Wang

Date: January 2, 2019

Price: $5300

  • Abstract
  • Stakeholder Toolkit

    This market report also includes a “stakeholder toolkit” to help the following parties manage the challenges and realize the growth opportunities that exist within the liquid biopsy space:

    • Entrepreneurs
    • Investors
    • Regulatory and reimbursement (payers)
    • Biopharma partners

  • Profiled in Report

    Select Liquid Biopsy Companies Profiled in Report

  • Major Trends

    Drivers

    Improvement of high sensitivity technologies (e.g., dPCR, next-generation sequencing (NGS) to accurately detect circulating nucleic acids, tumor cells, and exosomes
    Demonstration of clinical utility in particular use cases (e.g., T790M resistance monitoring)
    Inclusion in NCCN guidelines for metastatic if repeat tissue biopsy is not feasible
    Improved reimbursement prospects given the final CMS NGS NCD and Guardant360’s LCD by Palmetto GBA

    Moderators

    Variability in the level of circulating analytes by cancer type and stage
    Limited / low frequency events of circulating analytes
    Lack of large studies demonstrating clinical utility for certain use cases
    Limited or delayed reimbursement by commercial payers

  • Authors

    Dr. Stephane Budel

    Dr. Stephane Budel specializes in the market analysis of private to mid-cap companies with emerging to established technologies in the life science research tools and diagnostic spaces. He has deep genomics expertise, especially as it relates to clinical NGS. He has supported clients facing a broad range of challenging business issues, including R&D prioritization, evaluation of disruptive technologies, and commercial due diligences.

     

     

     

     

    Jessica Lee

    Jessica Lee has an extensive knowledge of market segments including neuromodulation, in-vitro diagnostics and molecular diagnostics. She has co-authored numerous market reports including DeciBio’s liquid biopsy, oncology biomarkers and NGS reports. Jessica completed her Master’s of Bioscience with a focus in Clinical & Regulatory Affairs at the Keck Graduate Institute (KGI) where she was a recipient of the Allergan Foundation Scholarship.

  • Why DeciBio Intelligence?

    Supplemental Analysis

    • 1 hour of analyst time for custom requests (e.g., deep dive on CellMax Life product differentiation)

    1-on-1 Phone Support

    • call with an author of the report to go through any nuances or report details

    Quality Assurance

    • full refund if not satisfied with report

    Instant Delivery

    • within 12 hours of receiving full payment